Skip to main content

Table 3 Duration of response in patients with laBCC receiving sonidegib 200 mg daily by central review

From: Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis

  mRECIST criteria ERIVANCE-like criteria
DOR, median, months, (95% CI) 26.1 (NE) 26.1 (NE)
Event-free probability estimate, %, (95% CI)
 6 months 86.4 (67.7–94.7) 90.8 (74.1–96.9)
 9 months 74.9 (54.4–87.2) 83.8 (65.3–93.0)
 12 months 64.9 (42.3–80.4) 69.2 (46.5–83.8)
  1. CI confidence interval, DOR duration of response, laBCC locally advanced basal cell carcinoma, mRECIST modified RECIST, NE not estimable, RECIST Response Evaluation Criteria in Solid Tumors